Status:

RECRUITING

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Lead Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborating Sponsors:

Mount Sinai Hospital, Canada

Conditions:

Chronic Rhinosinusitis With Nasal Polyps

Olfactory Disorder

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on ...

Eligibility Criteria

Inclusion

  • Patients older than 18 years old
  • Chronic rhinosinusitis with Nasal Polyps
  • Olfactory loss
  • Clinical indication for treatment with Dupilumab

Exclusion

  • Patients with olfactory loss from other causes such as:
  • Sinonasal malignancies
  • Trauma
  • Idiopathic olfactory loss
  • Use of cocaine
  • COVID-19 related olfactory loss
  • Pregnancy

Key Trial Info

Start Date :

July 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT04869436

Start Date

July 19 2021

End Date

December 1 2025

Last Update

December 20 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St. Joseph's Health Care

London, Ontario, Canada, N5A 4V2